The pilot project objectives broadly include the demonstration of the feasibility of identification of patient specific and therapeutically targetable genetic lesions using a newly developed, pediatric specific, next generation sequencing based panel which targets both DNA and RNA alterations in routine clinical specimens. This will be done in concert with the current development of a novel well defined cohort of pediatric large B-cell lymphoma with archival tissue and key clinical information